From migraine drugs to COVID vaccine spats, US lawsuits pile up
A busy week in US courts saw major pharma companies and biotech firms move to protect key therapies and research tools, with new lawsuits over migraine and cancer drug generics, and alleged misuse of COVID-19 vaccine tech.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
20 May 2026 The firm brings in a former VP at a biotech company, with biologics experience across antibodies, antibody drug-conjugates, peptides and gene and cell therapies.
19 May 2026 In the firm’s second IP conflict dispute in a year, a healthcare tech company claims Kirkland lawyers "committed the cardinal sin of trying to represent the conflicting interests of opposing parties".
19 May 2026 The award could rise to several billions under federal antitrust law, after the pharma company was found to have engaged in anticompetitive conduct over constipation drug Amitiza.